The Centers for Disease Control and Prevention (CDC) has alerted state health agencies of increasing concerns regarding human transmission of avian influenza following the report of three human deaths from confirmed avian influenza H5 infection in Vietnam. The Delaware Division of Public Health (DPH) is providing this Health Advisory to assure that Delaware health care providers are aware of the emerging threat.
While there is no evidence of avian influenza in humans or birds in Delaware at this time, DPH is enhancing our surveillance activities:
Questions about this Health Advisory, requests for laboratory testing and reports of suspected cases can be directed to DPH at 1-888-295-5156. This number is operational all the time. During non-business hours, it is available for emergencies.
This update reviews the current situation and the surveillance and diagnostic recommendations for avian influenza A (H5N1). The recommendations for avian influenza A (H5N1) remain at the enhanced level established in February 2004. As detailed in the recommendations below, vigilance in the clinical setting for avian influenza (H5N1) requires that health-care providers consistently obtain international travel and other exposure risk information for persons who have specified respiratory symptoms.
On August 12, 2004, the Vietnamese Ministry of Health officially reported to the World Health Organization (WHO) (see: http://www.who.int/csr/don/2004_08_12/en/ ) three human deaths from confirmed avian influenza H5 infection. Additional tests are needed to determine whether the virus belongs to the same H5N1 strain that caused 22 cases (15 deaths) in Vietnam and 12 cases (8 deaths) in Thailand earlier this year.
Cambodia, China, Indonesia, Japan, Laos, South Korea, Thailand and Vietnam were previously affected by widespread H5N1 outbreaks in poultry during early 2004. At that time, more than 100 million birds either died from the disease or were culled (killed) in efforts to contain the outbreaks. Human cases (34 in all) were reported only in Thailand and Vietnam. The last case officially confirmed and reported to the WHO by Vietnam occurred in February 2004.
Beginning in late June 2004, however, new lethal outbreaks of highly pathogenic avian influenza A (H5N1) among poultry were reported to the World Organization for Animal Health (OIE) by China, Indonesia, Thailand and Vietnam. The deaths reported by Vietnam on August 12 are the first reported human cases associated with this second wave of H5N1 infection among poultry. CDC is in communication with WHO and will continue to monitor the situation.
CDC recommends maintaining the enhanced surveillance efforts by state and local health departments, hospitals and clinicians to identify patients at increased risk for avian influenza A (H5N1) that were issued by CDC on February 3, 2004 (see: http://www.cdc.gov/flu/han020302.htm ). Guidelines for enhanced surveillance are:
Infection control precautions for H5N1 remain unchanged from the CDC interim recommendations published on February 3, 2004 (see: http://www.cdc.gov/flu/han020302.htm). These recommendations are further described in the CDC guidance document, "Interim Recommendations for Infection Control in Health-Care Facilities Caring for Patients with Known or Suspected Avian Influenza" (see: http://www.cdc.gov/flu/avian/professional/infect-control.htm).
Highly pathogenic avian influenza A (H5N1) is classified as a select agent and must be worked with under Biosafety Level (BSL) 3+ laboratory conditions. This includes controlled access double door entry with change room and shower, use of respirators, decontamination of all wastes and showering out of all personnel. Laboratories working on these viruses must be certified by the U.S. Department of Agriculture. CDC does not recommend that virus isolation studies on respiratory specimens from patients who meet the above criteria be conducted unless stringent BSL 3+ conditions can be met. Therefore, respiratory virus cultures should not be performed in most clinical laboratories and such cultures should not be ordered for patients suspected of having H5N1 infection.
Clinical specimens from suspect A (H5N1) cases may be tested by PCR assays using standard BSL 2 work practices in a Class II biological safety cabinet. In addition, commercial antigen detection testing can be conducted under BSL 2 levels to test for influenza.
Specimens from persons meeting the above clinical and epidemiologic criteria should be sent to CDC if:
Because the sensitivity of commercially available rapid diagnostic tests for influenza may not always be optimal, CDC also will accept specimens from persons meeting the above clinical criteria even if they test negative by influenza rapid diagnostic testing if PCR assays are not available at the state laboratory.
Requests for testing should come through the state and local health departments, which should contact (404) 639-3747 or (404) 639-3591 and ask for the epidemiologist on call before sending specimens for influenza A (H5N1) testing.